This section hosts guidelines, manuals and toolkits to strengthen public health practice.
Despite a global scarcity of Covid-19 vaccinations in 2021, the vaccine supply will no longer be a restricting factor in efforts to deliver more equitable coverage by the middle of 2022. A total of 344 vaccine candidates for Covid-19 have been produced or are currently being researched. After conditional clearance by national regulatory agencies or under the WHO Emergency Use Listing, 31 vaccination products are already in widespread use. There have been at least five different technology platforms deployed. “So why new Covid-19 vaccinations are still required?” The Covid-19 vaccinations that were first utilized during the epidemic may not be the best long-term option. To give cross-immunity against SARS-CoV-2 variants, the next generation of Covid-19 vaccines will need to have larger epitope coverage, confer a longer length of protection, and be easy to update in a timely manner for protection against any new variants. By accepting trade-offs, we should stay flexible in fine-tuning the optimum use of Covid-19 vaccines for the greatest impact on global public health. With more vaccination platforms accessible, we may be able to improve vaccine selection decision-making, as different vaccine platforms may be more suited to different age groups, subpopulations, and pregnant women. To maximize the benefits of each of these platforms, we may need to mix and blend vaccinations more frequently. Finally, currently available vaccinations are only somewhat effective against mild infection and transmission, which is further hampered by the emergence of novel omicron sub types. As a result, new vaccines that have a significant effect on lowering mild infection and transmission are needed to restrict the virus's spread and limit the speed at which new varieties evolve, even as the world tries to learn how to live with SARS-CoV-2.9.
To read the full article, please download the linked file.